67Ga-EDTMP was synthesized in a single step by adding 67GaCl3 to EDTMP solution. Dependences ofthe radiolabeling yield of 67Ga-EDTMP on EDTMP concentration, pH and reaction time were examined. Under theoptimum conditi...67Ga-EDTMP was synthesized in a single step by adding 67GaCl3 to EDTMP solution. Dependences ofthe radiolabeling yield of 67Ga-EDTMP on EDTMP concentration, pH and reaction time were examined. Under theoptimum conditions, the radiolabeling yield of 67Ga-EDTMP was more than 97%. A biodistribution experiment inmice showed that 67Ga-EDTMP was mainly absorbed by skeleton and reached 13.25% at 0.5 h after injecting, thenkept a high level in 72 h with a maximum value of 16.82% at 48 h. The results suggest that 67Ga-EDTMP might be apotential bone pain palliation radiopharmaceutical due to its high skeletal uptake, rapid blood clearance and relativelylow soft-tissue absorption. But further work must be done to determine whether 67Ga-EDTMP is useful in thetreatment of painful osseous metastases.展开更多
The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131（^131I）, phosphorous-32（^32P）, strontium-90（^90Sr）, and yttrium-90（^90Y）, have b...The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131（^131I）, phosphorous-32（^32P）, strontium-90（^90Sr）, and yttrium-90（^90Y）, have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.展开更多
基金the National Natural Science Foundation of China(No.1 9975066)
文摘67Ga-EDTMP was synthesized in a single step by adding 67GaCl3 to EDTMP solution. Dependences ofthe radiolabeling yield of 67Ga-EDTMP on EDTMP concentration, pH and reaction time were examined. Under theoptimum conditions, the radiolabeling yield of 67Ga-EDTMP was more than 97%. A biodistribution experiment inmice showed that 67Ga-EDTMP was mainly absorbed by skeleton and reached 13.25% at 0.5 h after injecting, thenkept a high level in 72 h with a maximum value of 16.82% at 48 h. The results suggest that 67Ga-EDTMP might be apotential bone pain palliation radiopharmaceutical due to its high skeletal uptake, rapid blood clearance and relativelylow soft-tissue absorption. But further work must be done to determine whether 67Ga-EDTMP is useful in thetreatment of painful osseous metastases.
文摘The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131（^131I）, phosphorous-32（^32P）, strontium-90（^90Sr）, and yttrium-90（^90Y）, have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.
